|
[1]
|
Kim KS. Toward neuroprotective treatments of Parkinson’s disease. Proc Natl Acda Sci USA 2017;114(15):3795 − 7. http://dx.doi.org/10.1073/pnas.1703362114CrossRef
|
|
[2]
|
Zhang ZX, Roman GC, Hong Z, Wu CB, Qu QM, Huang JB, et al. Parkinson’s disease in China: prevalence in Beijing, Xian, and Shanghai. Lancet 2005;365(9459):595 − 7. http://dx.doi.org/10.1016/S0140-6736(05)17909-4CrossRef
|
|
[3]
|
Dorsey ER, Constantinescu R, Thompson JP, Biglan KM, Holloway RG, Kieburtz K, et al. Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030. Neurology 2007;68(5):384 − 6. http://dx.doi.org/10.1212/01.wnl.0000247740.47667.03CrossRef
|